CAMBRIDGE, Mass.--(BUSINESS WIRE)--Agios Pharmaceuticals, the first biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced the appointment of Charles Sawyers, M.D., to its scientific advisory board. Dr. Sawyers, who currently serves as Chairman of Memorial Sloan-Kettering Cancer Center’s Human Oncology and Pathogenesis Program, is an internationally recognized clinician and scientist who led the clinical development of two breakthrough cancer therapies, Gleevec (imatinib) and Sprycel (dasatinib).
